Cynata Therapeutics (CYP) reported positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus mesenchymal stem cell product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). These findings, together with the excellent data from Cohort A, support the advancement of CYP-001 into a Phase 2 trial in GvHD
http://crweworld.com/article/news-p...-cohort-b-of-phase-1-trial-of-cyp-001-in-gvhd
Cynata Therapeutics (CYP) reported positive safety and efficacy...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.72M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 20.0¢ | $4.156K | 20.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 54635 | 3 |
View Market Depth
| Last trade - 15.43pm 26/04/2024 (20 minute delay) ? |
| CYP (ASX) Chart |